Capricor receives FDA rejection for Deramiocel in Duchenne muscular dystrophy
Capricor Therapeutics received a Complete Response Letter from the FDA for its resubmitted Deramiocel application, according to Reuters and a GlobeNewswire press release.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Biotech company Capricor Therapeutics said it received a Complete Response Letter from the U.S. Food and Drug Administration on its resubmitted Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. According to the letter, the regulator does not view the existing data as sufficient to prove effectiveness and points to other clinical shortcomings. The news was reported by Reuters and distributed through GlobeNewswire.
The company said it was deeply disappointed and believes the data support approval. As of September 30, 2026, Capricor held about $198.5 million in cash, equivalents and marketable securities, which it considers enough to fund operations for at least 12 months. It is also reviewing operating costs to extend its cash runway. Next steps will be shared after the company finishes evaluating the letter.
why it matters
For investors, the key question is whether Capricor can win approval or will need additional studies. The rejection delays any possible commercial launch of Deramiocel and makes the company's cash runway, which it is now trying to stretch by cutting costs, more important. The story matters mainly to Capricor shareholders and to those following rare-disease therapies.
market impact
Capricor shares: the FDA rejection casts doubt on the timing of its lead product's launch
- Capricor shares (CAPR) pressure down — the FDA rejection delays approval of the lead product and raises company-specific risk
tags
instruments
on polymarket
sources
- Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy — Reuters, 21 November 2026 at 00:56 UTC
- Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy — globenewswire.com, 21 November 2026 at 00:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗